Roivant Sciences Ltd (ROIV)

09:47 AM

Roivant Sciences Insider Sold Shares Worth $6,054,000, According to a Recent SEC Filing - Moomoo

09:47 AM

09:18 AM

Technical Reactions to ROIV Trends in Macro Strategies - Stock Traders Daily

09:18 AM

02:10 AM

Assessing Roivant Sciences (ROIV) Valuation After Strong Recent Share Price Momentum - Yahoo Finance

02:10 AM

May 25, 2026

Roivant Shelf Plan Raises Questions On Dilution And Pipeline Funding - simplywall.st

May 25, 2026

May 25, 2026

TD Cowen Raises its Price Target on Roivant Sciences (ROIV) - Insider Monkey

May 25, 2026

May 25, 2026

Litigation Windfall Driving Roivant Sciences’ Profit Swing Might Change The Case For Investing In Roivant Sciences (ROIV) - Yahoo Finance

May 25, 2026

May 25, 2026

Today's Analyst Rating | Roivant Sciences Price Target Raised to $31.5 by BofA Securities, UBS Downgrades Millicom International Cellular to Hold - Moomoo

May 25, 2026

May 25, 2026

Roivant Sciences Ltd. (ROIV) - DirectorsTalk Interviews

May 25, 2026

May 24, 2026

Roivant gains after mid-stage trial data for Immunovant’s main asset - MSN

May 24, 2026

May 24, 2026

Roivant shares climb on earnings beat despite revenue shortfall (ROIV) - MSN

May 24, 2026

May 23, 2026

Should Roivant’s One‑Off Driven Profitability Shift Require Action From Roivant Sciences (ROIV) Investors? - Sahm

May 23, 2026

May 22, 2026

[Form 4] Roivant Sciences Ltd. Insider Trading Activity - Stock Titan

May 22, 2026

May 22, 2026

Roivant anticipates $950M Moderna payment in July as it outlines 2H 2026 mosliciguat and IMVT-1402 readouts - MSN

May 22, 2026

May 22, 2026

ROIV Stock Price Prediction 2025-2026 | Roivant Sciences Ltd Forecast - 24/7 Wall St.

May 22, 2026

May 21, 2026

H.C. Wainwright reiterates Roivant Sciences stock rating on IMVT-1402 data By Investing.com - Investing.com South Africa

May 21, 2026

May 21, 2026

ROIV Maintained by Citigroup -- Price Target Raised to $42.00 - GuruFocus

May 21, 2026

May 21, 2026

Roivant Sciences Is Maintained at Buy by Citigroup - Moomoo

May 21, 2026

May 21, 2026

ROIV Reiterates by HC Wainwright & Co. -- Price Target Maintained at $34 - GuruFocus

May 21, 2026

May 21, 2026

Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy (NASDAQ:ROIV) - Seeking Alpha

May 21, 2026

May 21, 2026

Piper Sandler reiterates Roivant Sciences stock rating on trial progress By Investing.com - Investing.com Australia

May 21, 2026

May 21, 2026

Leerink raises Roivant Sciences stock price target on drug data By Investing.com - Investing.com South Africa

May 21, 2026

May 21, 2026

TD Cowen raises Roivant Sciences stock price target to $41 on trial data - Investing.com Australia

May 21, 2026

May 21, 2026

A Quick Look at Today's Ratings for Roivant Sciences(ROIV.US), With a Forecast Between $34 to $42 - Moomoo

May 21, 2026

May 21, 2026

Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2025 Earnings Call Transcript - Insider Monkey

May 21, 2026

May 21, 2026

Roivant Sciences Ltd. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ROIV) 2026-05-21 - Seeking Alpha

May 21, 2026

May 21, 2026

TD Cowen Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $41 - Moomoo

May 21, 2026

May 20, 2026

Roivant (ROIV) Climbs 15% on Swing to Profits - Insider Monkey

May 20, 2026

May 20, 2026

Roivant shares jump 10% on earnings beat despite revenue miss - Investing.com

May 20, 2026

May 20, 2026

Earnings call transcript: Roivant Sciences surprises with Q4 2026 EPS beat By Investing.com - Investing.com South Africa

May 20, 2026

May 20, 2026

Roivant Sciences Earnings Call Highlights High-Impact Pipeline - TipRanks

May 20, 2026

May 20, 2026

Roivant Sciences (ROIV) Q3 Loss Of US$265.9 Million Tests Long Term Bullish Narratives - simplywall.st

May 20, 2026

May 20, 2026

Earnings Call Summary | Roivant Sciences(ROIV.US) Q4 2025 Earnings Conference - 富途牛牛

May 20, 2026

May 20, 2026

Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $36.68, Implies 30% Upside - TradingView

May 20, 2026

May 20, 2026

Roivant/Immunovant Find Success In Tough-To-Treat RA, Where J&J Failed - Citeline News & Insights

May 20, 2026

May 20, 2026

Roivant Sciences (ROIV) Surges 15.2% on Strong Market Performanc - GuruFocus

May 20, 2026

May 20, 2026

Roivant Sciences stock hits all-time high of 30.35 USD By Investing.com - Investing.com Australia

May 20, 2026

May 20, 2026

Roivant Sciences Ltd (ROIV) Q4 2025 Earnings Call Highlights: Strategic Settlements and ... By GuruFocus - Investing.com Canada

May 20, 2026

May 20, 2026

Roivant Sciences (ROIV) Surges 14.8% to $32.38 - AlphaStreet

May 20, 2026

May 20, 2026

Roivant Sciences earnings beat by $0.57, revenue fell short of estimates - Investing.com India

May 20, 2026

May 20, 2026

Roivant reports Q4 FY2026 income on Moderna legal settlement - grafa.com

May 20, 2026

May 20, 2026

Why is Roivant Sciences stock surging today? By Investing.com - Investing.com South Africa

May 20, 2026

May 20, 2026

ROIV: High efficacy in refractory RA, strong cash, and major launches expected in the coming year - TradingView

May 20, 2026

May 20, 2026

2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug -- Barrons.com - Moomoo

May 20, 2026

May 20, 2026

Roivant Sciences Shares Jump 14.43% to $32.28 on Strong IMVT-1402 Rheumatoid Arthritis Data - International Business Times Australia

May 20, 2026

May 20, 2026

Roivant Sciences Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 - marketscreener.com

May 20, 2026

May 20, 2026

Earnings call transcript: Roivant Sciences Q4 2026 reveals strategic growth By Investing.com - Investing.com Australia

May 20, 2026

May 20, 2026

Sector Update: Healthcare - Moomoo

May 20, 2026

May 20, 2026

Roivant Sciences Q4 Earnings Call Highlights - Barchart.com

May 20, 2026

May 20, 2026

Immunovant Q4 Earnings Call Highlights - Yahoo Finance

May 20, 2026